Loading news...
Exploring the Fourth Quarter 2025 13F Filing John Rogers (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, providing insigh
Caisse Des Depots ET Consignations trimmed its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 36.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,374 shares of the biopharmaceutical company's stock after selling
One thing I've learned is the pendulum always swings. It is in our best approach to sell high and buy low. This has worked well for us, as our returns suggest.
Markets in 2026 are rewarding selectivity rather than size alone. Mega-cap leadership has narrowed, volatility has resurfaced, and investors are searching for a framework that can adapt to rotation. A barbell strategy that pairs AI enablers outside the Magnificent 7 with high-quality income names offers needed flexibility.
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
BMY's legacy drugs see sharp generic erosion in 2026, but Eliquis growth and guidance shape expectations as competition heats up in oncology.
Wesbanco Bank Inc. trimmed its stake in Bristol Myers Squibb Company (NYSE: BMY) by 5.5% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 245,082 shares of the biopharmaceutical company's stock after selling 14,341 shares during the period. Wesbanco Bank Inc.'s
BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.
The Vanguard Dividend Appreciation ETF and the Schwab U.S. Dividend Equity ETF offer different benefits for investors.
Oppenheimer Asset Management Inc. grew its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 6.4% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 531,538 shares of the biopharmaceutical company's stock after buying an additional 32,005
Candriam S.C.A. decreased its position in Bristol Myers Squibb Company (NYSE: BMY) by 10.5% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 897,263 shares of the biopharmaceutical company's stock after selling 105,641 shares during the quarter. Candriam S.C.A.'s holdings
BAAR, Switzerland--(BUSINESS WIRE)--Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence.
Birmingham Capital Management Co. Inc. AL lowered its stake in shares of Bristol Myers Squibb Company (NYSE: BMY) by 55.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,141 shares of the biopharmaceutical company's stock after selling 20,220
Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. BMY's 2026 guidance and Q4 2025 results exceeded consensus, with management consistently under-promising and over-delivering, setting up strong risk/reward. Patent cliffs for Eliquis and Opdivo loom in 2028, but a robust pipeline—seven registrational readouts in 2026—offers multiple upside catalysts.
Bristol Myers Squibb (NYSE: BMY) executives emphasized "focused execution" in 2025 and pointed to continued momentum entering 2026, as the company's growth portfolio increasingly offsets declines in legacy products. On the company's fourth-quarter earnings call, management highlighted strong contributions from newer brands, a slate of late-stage pipeline catalysts expected this year, and 2026 guidance that reflects
Chris Boerner, Bristol Myers Squibb CEO, joins CNBC's "Power Lunch" to discuss the company's quarterly earnings results, the drug pipeline and much more.
Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call Transcript
Investors were impressed by the company's performance in the final quarter of 2025. It beat analyst expectations on both the top and bottom lines.
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 400 points on Thursday.
Weekly Jobless Claims Exceed Expectations.